Navigation Links
Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
Date:9/3/2007

Publication in September issue of Nature Methods Shows Application of

Bioinformatics tools to Identify The Most Powerful Matrix Attachment

Regions Applied to Boost Transgene Expression.

GENEVA, Switzerland, Aug. 21 /PRNewswire/ -- Researchers at Selexis SA and The University of Lausanne have reported the identification of novel high-performance Genetic Elements also known as matrix attachment regions (or MARs). Data are presented using these novel high-performance Genetic Elements for increased gene expression in mammalian cells. This research, published online August 5 and in the September issue of the journal Nature Methods, demonstrates that using bioinformatics analysis, researchers computed putative novel genetic elements from the human genome and confirmed through cloning experiments that these newly identified genetic elements could significantly and stably increase transgene expression in mammalian cells when compared to previously known genetic elements.

"Having the ability to identify and apply the most powerful genetic elements for use in the rapid development of high-performance cell lines further improves our already powerful technology and service offering," said Dr. Igor Fisch, CEO of Selexis. "Selexis has been applying this experimental approach to identify of our most productive Selexis Genetic Elements, and in fact, we are planning the introduction of a new class of Selexis Genetic Elements later this year. These new elements will be smaller and more powerful and are showing even greater performance in boosting antibody expression in CHO cells," continued, Dr. Fisch. "We are confident our existing and new licensees and cell line development customers will benefit from this new offering."

About Selexis:

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services to speed the development of high performance mammalian cell lines. The
'/>"/>

SOURCE Selexis SA
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
3. FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4. Ariadne Genomics Announces the Release of PathwayStudio?Central, Client-Server Software for Biological Pathway Analysis
5. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
6. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
7. GlycoFi announces the first production of antibodies with human glycosylation in yeast
8. NHGRI announces new sequencing targets
9. CHAVI announces international search for genes affecting HIV response
10. NHGRI announces latest sequencing targets
11. MUHC announces a transplant first in Quebec

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...ers at Purdue University have discovered a new app... cord injuries using nano-spheres that could be in..., The synthetic "copolymer micelles" are drug-del...roughly 100 times smaller than the diameter of a r...how to deliver drugs for cancer treatment and othe...
(Date:11/6/2009)...in harmony with their arboreal hosts. But new rese...heir trees of choice, the ants can get destructive... in the November issue of the American Naturalist...ve trees, and it reopens a centuries-old debate on...s and certain species of plants and trees have coz...
(Date:11/5/2009)...rded a training grant in the amount of $2,756,719 ...rative Graduation Education and Research Training ...be awarded to Kent State. The grant, which is fund...t of 2009, runs through 2014. , The grant funds ...ic resource sensing (EARS). The purpose of the pro...
Breaking Biology News(10 mins):Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Ants are friendly to some trees, but not others 2Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 1Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 2Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 3Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 4Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 5Alcohol advertising self regulation not working as ads target younger drinkers 48311 1Alcohol advertising self regulation not working as ads target younger drinkers 48311 2Researchers estimate risk of transmission of Huntingtons disease to offspring among male carriers 48309 1Researchers estimate risk of transmission of Huntingtons disease to offspring among male carriers 48309 2
...the results are receiving rave reviews from apple ...nd research, a new apple cultivar has been introdu...ing program of the Illinois, New Jersey, and India...apple will be sold under the name ,WineCrisp,. Sch...urces and Environmental Sciences at the University...
...produce, which includes packaged lettuces, has gre...tbreaks associated with these products. To reduce ...s are used for decontamination once the food is ha...e fields is equally important. Researchers from th...f California, Davis and University of Arizona), le...
...tigators have uncovered a mechanism that helps exp...lar mood disorder, also protects the brain from da...n the May 1 issue of the Journal of Clinical Inve...how that lithium promotes DNA repair in healthy ce...gest that lithium treatment could offer a way to p...
Other Biology News:Apple enthusiasts welcome WineCrisp 2Protecting fresh-cut produce 2Lithium may help radiation target cancer, spare healthy tissue 2Lithium may help radiation target cancer, spare healthy tissue 3
(Date:11/5/2009)...K, N.Y., Nov. 5 BioSpeci...rmaceutical company developing first-in-class coll...ial results for the third quarter ended September ... September of this year, the FDA,s Arthritis Advis...f 12-0, the approval of XIAFLEX(TM) for the treatm...
(Date:11/5/2009)...RTH, Texas, Nov. 5 Wound...today that it has entered into a Letter of Intent ...al Health Technologies, Inc. (OTC Bulletin Board: ...0,000 in cash and debt, 4,000,000 shares of WNDM a...NDM on the Veriscrip technology being acquired fro...
(Date:11/5/2009)..., Calif., Nov. 5 WaferGe...eading developer of state-of-the-art genetic analy...s, Ph.D. has joined the company,s Scientific Advis...ng and commercializing novel molecular diagnostics...on the development of computational biology system...
(Date:11/5/2009)...MOUTH MEETING, Pa., Nov. 5 /PRNewswire-Asia-FirstC...("BMP Sunstone" or the "Company") today announced,...09 financial results on,Monday, November 9, 2009, ...ll hold a conference call at 5:00 pm ET on Novembe...Listeners may access the call by,dialing 1-888-713...
Breaking Biology Technology:BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4BMP Sunstone to Report Third Quarter 2009 Financial Results 2
...ioness Inc., an innovative provider of advanced ne...very from central nervous system disorders, announ...’s largest provider of inpatient rehabilitat...ity of the NESS H200 Hand Rehabilitation System an...bilitation hospitals nationwide. , ...
...RUG DEVELOPMENT, ROCKVILLE, Md., July 30 Stem ce...d that Dr. Thomas Hazel will be,rejoining the comp... be,working with Dr. Karl Johe, Neuralstem,s Chair...ny,s upcoming clinical trial for ALS,(Amytrophic L...mplete,development of Neuralstem,s small molecule ...
... Development Of Lead Drug Candidates, MARKHAM, ON...d the,closing of a CDN $45 million Series C financ...ubishi Tanabe Pharma Corporation ("MTPC"), and sup... Vengrowth Advanced Life,Sciences Fund Inc., Caiss...an Medical Discoveries Fund Inc., T(2)C(2)/Bio 200...
Other Biology Technology: Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 3Neuralstem Fills Key Product Development Position 2Cytochroma Closes $45 Million Series C Financing 2Cytochroma Closes $45 Million Series C Financing 3
...nity Life Sciences can provide custom microplate c...croplate processing equipment that dispenses and w...mmodate virtually any lot size of the following fo... 8 and 12 well strips, 96 well microplate, ...
Cytomics FC 500 Series Flow Cytometry Systems from Beckman Coulter
Mynox Mycoplasma Elimination Reagent from Minerva Biolabs GmbH
Mynox Mycoplasma Elimination Reagent from Sigma-Aldrich
Biology Products: